Category: Psychedelic Bulletin - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA Funds Psychedelic Therapy for Veterans; AbbVie Paid $900M Upfront for Psychedelic Candidate

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA Funds Psychedelic Therapy for Veterans; AbbVie Paid $900M Upfront for Psychedelic Candidate

Post published:November 7, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M

Post published:October 31, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed

Post published:October 24, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #210: Compass Exec Defends Minimal Support Model in Stockholm; IV Ketamine Outperforms Esketamine Nasal Spray in Retrospective Study; Reunion Advances RE104 in Adjustment Disorder; Mindstate Wraps Phase I

Pα+ Psychedelic Bulletin #210: Compass Exec Defends Minimal Support Model in Stockholm; IV Ketamine Outperforms Esketamine Nasal Spray in Retrospective Study; Reunion Advances RE104 in Adjustment Disorder; Mindstate Wraps Phase I

Post published:October 3, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #209: Aussie Insurer Covers Psilocybin for TRD; atai Scores $11.4M NIDA Grant; First Look at Real-World Outcomes from Oregon Psilocybin Clients; Pipeline Updates

Pα+ Psychedelic Bulletin #209: Aussie Insurer Covers Psilocybin for TRD; atai Scores $11.4M NIDA Grant; First Look at Real-World Outcomes from Oregon Psilocybin Clients; Pipeline Updates

Post published:September 24, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

Post published:September 5, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision; AbbVie-Gilgamesh Deal Viewed as Validation

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision; AbbVie-Gilgamesh Deal Viewed as Validation

Post published:August 28, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions

Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions

Post published:August 8, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in U.S.; FDA Moves to Ban Kraton Compound 7-OH; What Is Sinema Selling?

Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in U.S.; FDA Moves to Ban Kraton Compound 7-OH; What Is Sinema Selling?

Post published:August 1, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could Streamline Schedule I Research

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could Streamline Schedule I Research

Post published:July 25, 2025
Post category:Psychedelic Bulletin Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.